Barriers and opportunities for gemcitabine in pancreatic cancer therapy
American Journal of Physiology-Cell Physiology · 01.02.2023 · 324 (2) · C540-C552
DOI: 10.1152/ajpcell.00331.2022 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Physiology-Cell Physiology, erschienen am 01.02.2023. Verfasst von Alica K Beutel und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology and Biochemistry, University of California, Irvine, California. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 151-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, University of California, Irvine, Deutsche Krebshilfe.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDA) has become one of the leading causes of cancer-related deaths across the world. A lack of durable responses to standard-of-care chemotherapies renders its treatment particularly challenging and largely contributes to the devastating outcome. Gemcitabine, a pyrimidine antimetabolite, is a cornerstone in PDA treatment. Given the importance of gemcitabine in PDA therapy, extensive efforts are focusing on exploring mechanisms by which cancer cells evade gemcitabine cytotoxicity, but strategies to overcome them have not been translated into patient care. Here, we will introduce the standard treatment paradigm for patients with PDA, highlight mechanisms of gemcitabine action, elucidate gemcitabine resistance mechanisms, and discuss promising strategies to circumvent them.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biology and Biochemistry, University of California, Irvine, California.
- Department of Internal Medicine, University Hospital Ulm, Ulm, Germany.
- Chao Family Comprehensive Cancer Center, Orange, California.
ORCID-Profile: Christopher J Halbrook
Förderung
- NCI NIH HHS
- University of California, Irvine
- Deutsche Krebshilfe
- HHS | NIH | National Cancer Institute
- National Pancreas Foundation
- Sky Foundation
- V Foundation for Cancer Research
Zitieren
APA
Beutel, A. K., & Halbrook, C. J. (2023). Barriers and opportunities for gemcitabine in pancreatic cancer therapy. American Journal of Physiology-Cell Physiology, 324(2), C540-C552. https://doi.org/10.1152/ajpcell.00331.2022
Vancouver
Beutel AK, Halbrook CJ. Barriers and opportunities for gemcitabine in pancreatic cancer therapy. American Journal of Physiology-Cell Physiology. 2023;324(2):C540-C552. doi:10.1152/ajpcell.00331.2022
BibTeX
@article{Beutel2023,
author = {Beutel, Alica K and Halbrook, Christopher J},
title = {Barriers and opportunities for gemcitabine in pancreatic cancer therapy},
journal = {American Journal of Physiology-Cell Physiology},
year = {2023},
volume = {324},
number = {2},
pages = {C540--C552},
doi = {10.1152/ajpcell.00331.2022}
}
EUVIMED